drugset

drugset / Trial / NCT02848794

Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma

NCT02848794 ↗

Phase 1/2 Unknown 40 enrolled The First People's Hospital of Lianyungang Lianyungang Hospital Affiliated Bengbu Medical College · collab Shandong Cancer Hospital and Institute · collab Suzhou Kowloon Hospital · collab The Affiliated Hospital of Qingdao University · collab Yankuang Group General Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

The study is aimed to evaluate the efficacy and safety of Apatinib and Irinotecan in patients with recurrent high-grade glioma.

Timeline

Start: 2016-07
Primary completion: 2018-07
Completion: 2018-07

Publications

Wang L, Liang L, Yang T, Qiao Y, Xia Y, Liu L, Li C, Lu P, Jiang X. A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study. Medicine (Baltimore). 2017 Dec;96(49):e9053. doi: 10.1097/MD.0000000000009053.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	125 mg/m2	Intravenous
Subject	Rivoceranib	Small molecule	500 mg	Oral

Indications